Scancell chief hints at future NASDAQ listing

Richard Goodfellow, chief executive of Scancell (LON:SCLP), says the immuno-oncology specialist could explore the option of a NASDAQ listing once it has built up its North American profile. The CEO was speaking to Proactive following the announcement of two new appointments – Dr John Chiplin, who will join the board as a non-executive director, and Dr Peter Brown, who is to be an advisor to the drug developer. The former brings with him a wealth of industry experience, having been instrumental in the NASDAQ listing of Australia-quoted Benitec Biopharma.. Scancell’s first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials.

It's only fair to share...Tweet about this on TwitterShare on FacebookShare on TumblrShare on Google+Digg thisShare on LinkedInPin on PinterestShare on VKShare on RedditPrint this pageEmail this to someone
Flattr the authorShare on StumbleUponShare on YummlyBuffer this page

Leave a Reply

Your email address will not be published. Required fields are marked *